Background {#Sec1}
==========

Factor Xa (FXa) inhibitors are direct oral anticoagulants (DOACs) and safe and effective alternatives to warfarin in preventing stroke in patients with atrial fibrillation and treating venous thrombosis \[[@CR1]\]. Apixaban (Eliquis©; Bristol-Myers Squibb/Pfizer EEIG, Uxbridge, United Kingdom) is an oral, direct-acting FXa inhibitor with a half-life of approximately 12 hours. The treatment is less complicated than warfarin treatment, as it consists of a fixed dose which does not require monitoring \[[@CR2]\]. Because of the convenience and proven efficacy, the prescription rate of DOACs is increasing worldwide \[[@CR3]\]. Consequently, the number of patients who are anticoagulated with DOACs and need emergency surgery for coexisting conditions increases accordingly. However, reversal of the effect of FXa inhibitors is still a matter of debate. The antidote andexanet alfa has shown promising results in clinical studies, but it is still not commercially available \[[@CR4]\]. Furthermore, this antidote is not a good option for reversing the FXa inhibitor effect before cardiovascular surgery, as it is unspecific and reverses all FX inhibitors, including heparinization, that are required during cardiopulmonary bypass. Guidelines providing a strategy to manage bleeding complications or emergency surgery in FXa inhibitor-treated patients are not conclusive and suggest 4-factor prothrombin complex concentrate (4-PCC) or activated prothrombin complex concentrate (aPCC) as reversal agents \[[@CR5]\]. 4-PCC contains factor II, VII, IX, and X in their inactive zymogen forms and is used to reverse the anticoagulation effect of warfarin. aPCC is used to treat hemophiliacs with inhibitor and contains activated FVII in addition to factor II, IX, and X. The documentation of the ability of these reversal agents to reverse the anticoagulation of FXa inhibitors is limited, and apart from one cohort study evaluating the effect of 4-PCC as reversal agent in apixaban-treated patients undergoing major bleeding \[[@CR6]\], only animal studies, *in vitro* studies, and case reports exist \[[@CR7]--[@CR12]\]. In the following case series we present three patients in whom aPCC was used to reverse the anticoagulation effect of apixaban before emergency cardiovascular surgery. The reversal effect was assessed both clinically by the surgeon and by coagulation tests.

Case presentation {#Sec2}
=================

Case 1 {#Sec3}
------

A 63-year-old white man under treatment with apixaban 5 mg twice daily due to atrial fibrillation was hospitalized after rapidly developing symptoms of heart failure. Four weeks earlier he had had a re-implantation of a biological aortic valve because of infectious deposits on the mechanical valve and was still under antibiotic treatment at the time of admission. He had no previous history of bleeding disorders. He had taken his morning dose of apixaban and presented with respiratory distress, fever, and hypotension. His blood samples showed a hemoglobin level of 97 g/L, leukocyte count of 10.3 × 10^9^/L, thrombocyte count of 157 × 10^9^/L, estimated glomerular filtration rate (GFR) of 45 ml/minute, and C-reactive protein concentration of 337 mg/L. He had normal liver function tests. Both prothrombin time (PT) and activated partial thromboplastin time (aPTT) were prolonged (Table [1](#Tab1){ref-type="table"}). An echocardiography revealed an extreme aorta stenosis and a left ventricle dysfunction. His condition deteriorated rapidly, and surgery to replace the aortic valve was needed immediately. There was no time to await the wash-out effect of apixaban. Due to recent apixaban tablet intake and need for major surgery with potentially large blood loss, aPCC (FEIBA^©^) 3000 IU (25 IU/kg) was administered over a 10-minute period prior to surgery to reverse the anticoagulation effect of apixaban. Afterwards, cardiopulmonary bypass was established with full heparinization, which was monitored with aPTT. Before and after the aPCC treatment, but before starting the heparin infusion, blood samples were collected in citrated test tubes prefilled with corn trypsin inhibitor (CTI) and in test tubes containing only citrate. The apixaban concentration was measured by anti-FXa activity (aFXa) assay, and coagulation status was assessed by thromboelastometry (ROTEM®; Tem Innovations, Munich, Germany) using minimal tissue factor activation \[[@CR13], [@CR14]\], PT, and aPTT before and after aPCC treatment. ROTEM™ clotting time (CT) was shortened from 1900 to 740 seconds, and clot formation time (CFT) was shortened from 353 to 191 seconds. PT and aPTT were reduced from 62 to 20 and 58 to 48, respectively. Surgery was performed successfully without excessive bleeding or thromboembolic complications. Hence, administering aPCC improved hemostasis, which was assessed clinically by the surgeon and measured by global coagulation tests (Fig. [1a, b](#Fig1){ref-type="fig"}) (Table [1](#Tab1){ref-type="table"}).Table 1Laboratory results of patients 1 and 2 before and after reversal of the apixaban effectCase 1Case 2Before aPCCAfter aPCCBefore aPCCAfter aPCCCT (seconds)19007401482807MCF (mm)60556866CFT (seconds)353191353159PT (seconds)622026\< 17aPTT (seconds)58483327aFXa (μg/L)6968152152*aFXa* anti-factor Xa activity, *aPCC* activated prothrombin complex concentrate, *aPTT* activated partial prothrombin time, *CFT* clot formation time, *CT* clotting time, *MCF* maximum clot firmness, *PT* prothrombin timeFig. 1Thromboelastometry curves of patient 1 and patient 2. **a** Thromboelastometry curves before administering activated prothrombin complex concentrate 3000 IU. **b** Thromboelastometry curves after administering activated prothrombin complex concentrate 3000 IU. Clotting time shortened after administering activated prothrombin complex concentrate 3000 IU. *aPCC* activated prothrombin complex concentrate

Case 2 {#Sec4}
------

A 65-year-old white man waiting for heart transplantation because of end-stage heart failure was under treatment with apixaban 5 mg twice daily because of atrial fibrillation. He had no other comorbidities and had no previous history of bleeding disorders. On the day a heart from a deceased donor was available, he had taken his morning dose of apixaban. Heart transplantation surgery was coordinated the same evening. His blood test results at the time of admission showed normal blood counts, creatinine level of 156 μmol/L, estimated GFR 40 ml/minute, PT 26 seconds and aPTT 33 seconds. The apixaban concentration was 152 μg/L. Because of the recent tablet intake and the great bleeding risk during and after the procedure, it was decided to administer aPCC 3000 IU immediately before surgery. His body weight was 108 kg, which means that the dose administered was 28 IU/kg. The surgery was uncomplicated, and so was the postoperative period. No bleeding complications or thromboembolic events were seen. CT was reduced by more than 50% (from 1482 seconds to 807 seconds), and CFT was reduced accordingly (Fig. [1a, b](#Fig1){ref-type="fig"}). PT and aPTT were also reduced after aPCC treatment (Table [1](#Tab1){ref-type="table"}).

Case 3 {#Sec5}
------

A 68-year-old white man taking apixaban 5 mg twice daily because of atrial fibrillation was hospitalized with acute chest pain. He had no other comorbidities and no prior bleeding disorders in the past. A quickly performed computed tomography scan showed a type A aortic dissection, and acute surgery was required. He had taken the last dose of apixaban the same morning, 8 hours earlier. He had normal kidney function at the time of admission. For the same reasons as in the previous cases, it was decided to administer aPCC 3000 IU (29 IU/kg) prior to surgery. The surgery went well without excessive bleeding, but after 4 hours postoperative pericardial bleeding occurred, causing tamponade. He was re-operated twice the same night because of bleeding, and he received massive transfusion with erythrocytes, thrombocytes, plasma, and, later, prothrombin complex concentrate, fibrinogen, aPCC, and recombinant activated FVII. By the next morning, approximately 8 hours later, he stopped bleeding and was stabilized. Unfortunately, the blood samples were contaminated with heparin, so there are no ROTEM™ results in this case. The apixaban concentration was 98 μg/L, but this value was not known at the time of surgery and did not influence the treatment before or after surgery. Postoperatively, no thromboembolic complications were observed, but he died of septic shock after 6 weeks in the intensive care unit.

Discussion {#Sec6}
==========

The optimal method to reverse the effect of FXa inhibitors in cases of emergency surgery or major bleeding is not known. In this case series, we report on the cases of three patients anticoagulated with apixaban who required emergency cardiovascular surgery. By administering aPCC prior to surgery, the anticoagulation effect was reversed successfully, according to measurements of global coagulation assays and clinical assessment.

The therapeutic level of apixaban is not yet established, but aFXa in patients anticoagulated with apixaban 5 mg twice daily have peak values of 91 to 321 μg/L and trough values of 41 to 230 μg/L \[[@CR2]\]. In the cases reported here, the aFXa level calibrated for apixaban was between 68 and 152 μg/L at the time of admission, which confirms that the patients were fully anticoagulated.

Cardiovascular surgery has a high risk of bleeding complications and involves cardiopulmonary bypass treatment, including full heparinization. For this reason it was decided to reverse the anticoagulation effect of apixaban. In the acute setting, aPCC 3000 IU (25-30 IU/kg) was administered over 10 minutes immediately before initiating heparinization and cardiopulmonary bypass treatment to perform major cardiovascular surgery. This dose was chosen to minimize the risk of thromboembolic complications. *In vitro* studies have shown that aPCC at the suggested dose might overcorrect the hemostatic parameters \[[@CR7], [@CR9]\], and patients treated with apixaban already have a risk of thromboembolic complications. Another study has shown that 25 IU/kg reverses the hemostatic parameters altered by apixaban quickly and sufficiently \[[@CR10]\]. A single case report also supports the use of this dose \[[@CR15]\].

In addition to a clinical assessment of hemostasis, the reversal effect of aPCC was measured by thromboelastometry, which provides information about time until clot formation and the viscoelastic properties of the clot. Previous studies performed with the same method have shown that the healthy, not anticoagulated control group obtained an average CT of 705 seconds (± 210 seconds) \[[@CR9]\]. This means that the reported cases of patients obtained a CT corresponding to normal value after receiving aPCC. AFXa activity was, not surprisingly, unaltered after aPCC treatment, as the activated clotting factors improve the hemostasis by bypassing the FXa inhibition of apixaban but do not directly influence the apixaban concentration. The fact that the conventional coagulation tests PT and aPTT are not valuable indicators of the DOAC effect \[[@CR16]\] was confirmed in this case series. In cases 2 and 3 the values of aPTT were within the normal range before reversal of the apixaban effect, but in case 1, aPTT was higher than expected when taking the apixaban concentration in consideration. We do not know the reason for this, but one possible explanation may be that there was a situation with disseminated intravascular coagulation, as the patient had an infection at time of admission. In patient 1, the concentration of apixaban was surprisingly high 24 hours after last intake, which may be explained by the impaired kidney function.

The main limitation of this case series is that only a few cases are described. The risk of selection bias, however, is reduced by consecutively including patients. The lack of a control group is another limitation; however, the patients served as their own controls because laboratory tests were performed before and after treatment. In two of three patients, the reversal was successful, and this may also have been the case in the third patient. The postoperative bleeding could have been caused by an arterial bleeding, and reversing the anticoagulation effect would not have prevented this. The case report only described the use of one of the suggested treatment options, and randomized studies are needed to provide us with the optimal treatment in cases of major bleeding or the need for emergency cardiovascular surgery in FXa inhibitor-treated patients.

Conclusions {#Sec7}
===========

This case series describes the use of aPCC in a setting where reversal of the anticoagulation effect of apixaban was needed before acute cardiovascular surgery. Our report demonstrates that hemostasis markedly improved, as assessed clinically and by coagulation tests after administering aPCC 25-29 IU/kg. None of these surgeries was complicated by excessive bleeding during surgery. However, one of the cases was complicated by postoperative bleeding. The safety of the treatment was demonstrated, as in none of the cases did thromboembolic complications occur (Table [2](#Tab2){ref-type="table"}).Table 2Apixaban concentration, treatment, and clinical courseaFXa (μg/L)Time from last apixaban dose to surgeryaPCC doseExcessive perioperative or postoperative bleedingThromboembolic complicationsPatient 16924 hours25 IU/kgNoNoPatient 215210 hours28 IU/kgNoNoPatient 3989 hours29 IU/kgYesNo*aFXa* anti-factor Xa activity, *aPCC* activated prothrombin complex concentrate
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